Nexus Surgical And Medicare Ltd vs Transgene Biotek Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Nexus Surgical and Medicare Ltd is ₹ 25.05 as of 23 Oct 15:30 . The P/E Ratio of Nexus Surgical and Medicare Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Uma Medicare Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Transgene Biotek Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Nexus Surgical and Medicare Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Uma Medicare Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Transgene Biotek Ltd changed from ₹ 34.7 crore on March 2021 to ₹ 25.38 crore on March 2025 . This represents a CAGR of -6.06% over 5 years The revenue of Nexus Surgical and Medicare Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Uma Medicare Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Transgene Biotek Ltd for the Jun '26 is ₹ 0.06 crore as compare to the Mar '26 revenue of ₹ 0.2 crore. This represent the decline of -70% The ebitda of Nexus Surgical and Medicare Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Uma Medicare Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Transgene Biotek Ltd for the Jun '26 is ₹ -0.06 crore as compare to the Mar '26 ebitda of ₹ -0.13 crore. This represent the decline of -53.85% The net profit of Nexus Surgical and Medicare Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The net profit of Uma Medicare Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The net profit of Transgene Biotek Ltd changed from ₹ 0.2 crore to ₹ -0.39 crore over 9 quarters. This represents a CAGR of NaN% The Dividend Payout of Nexus Surgical and Medicare Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Uma Medicare Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Transgene Biotek Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Nexus Surgical and Medicare Ltd

Nexus Surgical & Medicare Limited was formerly incorporated as Nexus Commodities and Technologies Limited in 1992.
The Company came out with a public issue in Aug.'96 to part-finance the project.
Later, the name of the Company was changed to Nexus Surgical & Medicare Limited in August 2020.
The Company is engaged into trading of medical essentials.
Prior to this, it was promoted by a group of technocrats to manufacture and market premium consumer durables and domestic appliances. The Company is a wholesale dealer dealing in various sizes of disposal syringe (with and without needle) and pouches of various size used for storage of sterilized equipment and materials.

About Transgene Biotek Ltd

Founded in March 1990 by Dr. Koteswara Rao, Transgene Biotek Limited was one of the first Biotechnology companies in India.
Although Transgene began life manufacturing and selling diagnostic kits, it soon moved on to true biotech research, including the research and development of vaccines, oncology , New drug delivery technologies etc.
The first major success came when it sold genetically engineered recombinant Hepatitis B vaccine technology along with novel and patented process in 1999 to the Serum Institute, Pune. Presently, the Company is engaged in the business of research and development and manufacture of various medical reagents, both chemical and immuno-diagnostic reagents for qualitative and quantitative estimation of bio-chemical parameters and diagnosis of diseases respectively.

FAQs for the comparison of Nexus Surgical and Medicare Ltd and null

Which company has a larger market capitalization, Nexus Surgical and Medicare Ltd or Uma Medicare Ltd?

Market cap of Nexus Surgical and Medicare Ltd is 13 Cr while Market cap of Uma Medicare Ltd is 0 Cr

What are the key factors driving the stock performance of Nexus Surgical and Medicare Ltd and Uma Medicare Ltd?

The stock performance of Nexus Surgical and Medicare Ltd and Uma Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Nexus Surgical and Medicare Ltd and Uma Medicare Ltd?

As of October 25, 2026, the Nexus Surgical and Medicare Ltd stock price is INR ₹25.05. On the other hand, Uma Medicare Ltd stock price is INR ₹0.0.

How do dividend payouts of Nexus Surgical and Medicare Ltd and Uma Medicare Ltd compare?

To compare the dividend payouts of Nexus Surgical and Medicare Ltd and Uma Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.